DSM updates market on strategy progress at Capital Markets Days
Royal DSM, the global Life Sciences and Materials Sciences company, today and tomorrow will update the financial community at its annual Capital Markets Days on the progress made with its DSM in Motion: driving focused growth strategy. The company also confirms its 2011 outlook.
Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented: 'Against a backdrop of increased uncertainties related to the global economy, our completed transformation into a Life Sciences and Materials Sciences company has positioned DSM well with a balanced, relatively resilient portfolio in health, nutrition and materials. We are making good progress in executing our strategy and we are on track to achieve our 2013 targets.'
During today's conference, DSM will update the investment community on progress made with DSM in motion: driving focused growth. This strategy marks the shift from an era of intensive portfolio transformation to a strategy for the coming years of maximizing sustainable and profitable growth of 'the new DSM'. The company believes good progress is being made towards achieving the EBITDA target of € 1.4 to 1.6 billion in 2013, in conjunction with a ROCE of more than 15%.
The following information will be given:
· DSM is on track in achieving its ambitious financial targets for 2013 and 2015
· DSM reports good progress towards achieving its sustainability aspirations, recently it was named once again the supersector leader in the Dow Jones Sustainability Index
· Nutrition: good progress is achieved with the integration and profit growth of Martek; the strong Swiss Franc impacts the results of the cluster also in Q3; the cluster is on track regarding its growth strategy
· Pharma: the just established DSM Sinochem Pharmaceuticals-JV aims to increase its sales to > € 600 mln with an EBITDA margin > 15% by 2015; a partnership for DPP is being pursued
· Performance Materials: strong growth is based on innovative sustainable solutions enhanced by selective acquisitions & partnerships
· Polymer Intermediates: will further strengthen its global leadership position; 2nd production line in China is being built
· Bio-based Products & Services: with number one position in yeast and top 3 position in enzymes DSM is well positioned for 2nd generation (cellulosic) bio-ethanol; a large scale bio-based succinic acid plant is under construction
· Biomedical: continued strong growth (> 15% per year) anticipated
· DSM confirms outlook: 2011 is expected to be a strong year; good progress towards achieving the 2013 targets, assuming no major changes to the overall business assumptions for the full year
Webcast
The DSM Capital Markets Days can be followed today from 15.30 until 18.00 hrs (CET) via an audio webcast. The presentations can be downloaded from DSM's website as of 13.00 hrs (CET). For a link see the Investors section on www.dsm.com
DSM - Bright Science. Brighter Living.(TM)
Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com
For more information:
DSM Corporate CommunicationsHerman Bettentel. +31 (0) 45 5782017 fax +31 (0) 45 5740680 e-mail media.relations@dsm.com |
DSM Investor Relations Hans Vossen tel. +31 (0) 45 5782864 fax +31 (0) 10 4590275 e-mail investor.relations@dsm.com |
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
-
Most popular related searches
Related news
-
The Chinese University of Hong Kong and Aurora Medical Technology Hong Kong to collaborate on breast cancer research program
Aurora Medical Technology Hong Kong (Aurora-HK) and The Chinese University of Hong Kong (CUHK) are pleased to announce the completion of a landmark collaboration agreement leveraging the shared interests and diverse expertise of the two entities.Led by Winnie chiu-wing Chu MD, Professor of radiology at CUHK and Abraham Morse MD, Medical Director of Aurora, the joint project will investigate the potential advantages and challenges of using breast-dedicated MRI for first-line breast cancer screening in Chinese...
-
Riskonnect Addresses Financial Services and Healthcare Market Risks with New Platform Capabilities
Riskonnect, the leader in integrated risk management (iRM) solutions, today announces the latest version of its platform Riskonnect 2021.1. Among other enhancements, the release delivers two new major capabilities within the governance, risk, and compliance (GRC) suite specifically designed to help UK financial services organizations build resilience and improve decision making. The release also includes several new features within Riskonnect’s Healthcare Patient Safety and Risk Management Solution that...
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent (p5.27; cycle threshold value < 27.5) at day 7 compared to placebo, meeting the primary endpoint. In addition,...
-
Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals Joins ExThera Medical Board of Directors
Professor Lakhmir Chawla, MD, has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company whose Seraph 100 Microbind Affinity Blood Filter is authorized in the United States to treat critically ill COVID-19 patients. Dr. Chawla also serves as the Chair of the Scientific Advisory Board at the company Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI), vasopressors, and septic shock. He remains an active investigator in the...
-
Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The fireside chat will take place on Wednesday, March 17, 2021 at 2:30 p.m. ET / 11:30 a.m. PT. To access the webcast, go to the...
Customer comments
No comments were found for DSM updates market on strategy progress at Capital Markets Days. Be the first to comment!